Clinical characteristics and prognostic analysis of SMARCA4‐deficient non‐small cell lung cancer

Author:

Liang Xiyue1ORCID,Gao Xianzheng2,Wang Feng1,Li Shenglei2,Zhou Yashu1,Guo Peng1,Meng Yuanyuan1,Lu Taiying1

Affiliation:

1. Department of Oncology The First Affiliated Hospital of Zhengzhou University Zhengzhou China

2. Department of Pathology The First Affiliated Hospital of Zhengzhou University Zhengzhou China

Abstract

AbstractPurposeTo improve the understanding of special types of tumors, we summarized and analyzed the clinicopathological features and prognostic factors of SMARCA4‐deficient non‐small cell lung cancer (SMARCA4‐dNSCLC).MethodsWe selected 105 patients with SMARCA4‐dNSCLC and 221 patients with SMARCA4‐intact non‐small cell lung cancer (SMARCA4‐iNSCLC) by performing immunohistochemical analysis of 1520 NSCLC samples, and we assessed the patients' clinicopathological features and survival state.Results(1) SMARCA4‐dNSCLC was significantly associated with older age, male sex, smoking history, larger invasive tumor size, higher tumor proliferation index (Ki‐67), more adrenal metastases, more lymph node metastases, and few EGFR mutations (p < 0.05). The tumors were mostly negative for thyroid transcription factor‐1 (TTF‐1), CD34, and p40 and positive for cytokeratin 7 (CK7) in immunohistochemistry (IHC). Nineteen SMARCA4‐dNSCLC patients mostly had TP53, SMARCA4, and LRP1B mutations, and 48% of them had SMARCA4 frameshift mutations. SMARCA4‐dNSCLC patients have a worse prognosis than SMARCA4‐iNSCLC patients (HR: 0.27; 95% CI: 0.17–0.45). The overall survival (OS) of patients with stage III SMARCA4‐dNSCLC was worse than that of patients with SMARCA4‐iNSCLC, and the OS of stage IV SMARCA4‐dNSCLC patients was also worse than that of SMARCA4‐iNSCLC patients (p < 0.01). (2) Multivariate regression analysis showed that sex (HR: 4.12; 95% CI: 1.03–16.39) and smoking history (HR: 2.29; 95% CI: 1.04–5.02) had significant effects on the survival time of SMARCA4‐dNSCLC patients. In SMARCA4‐dNSCLC patients without distant metastases (stage I–III), patients with stage N2 or N3 lymph node metastases (HR: 6.35; 95% CI: 1.07–37.47) had a poor prognosis. Among patients with SMARCA4‐dNSCLC who were treated and had distant metastases (stage IV), male patients and patients treated with immunotherapy combined with chemotherapy showed a longer median overall survival (mOS).ConclusionSMARCA4‐dNSCLC has unique clinicopathological features and a shorter survival prognosis than SMARCA4‐iNSCLC. The efficacy of immunotherapy combined with chemotherapy needs to be observed for longer periods.

Funder

Henan Medical Science and Technique Foundation

National Basic Research Program of China

Publisher

Wiley

Subject

Cancer Research,Radiology, Nuclear Medicine and imaging,Oncology

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3